03 April 2020

Call it by the correct name - pulmonary hypertension not pulmonary arterial hypertension. Growing recognition of the global health impact for a well-recognised condition and the role of the Pulmonary Vascular Research Institute

Call-it-by-its-correct-name.jpg

May 5th signals World Pulmonary Hypertension Day and, whilst the world is currently focusing on the coronavirus pandemic, it is important to remember our patients with this condition, which continues to exert a major disease burden in all low, middle and high income countries.  

Call-it-by-another.jpg

Although pulmonary hypertension has long been recognised to complicate many common diseases, especially left-sided heart disease and lung disease, most basic, translational and clinical scientists together with the pharmaceutical industry have, to date,  focused  predominantly on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension1. Both entities are rare, leading to the erroneous belief that pulmonary hypertension in general is a rare condition, and not worthy of major global focus.

This editorial summarises the global incidence and prevalence of pulmonary hypertension and considers implications for health-care providers, policy makers, and future research strategies.


Comments (1)

  • profile picture of Ernesto Juaneda

    09 May 2020 14:28

    Ernesto Juaneda

    Excelent and clarifyng wor: Pulmonary hypertension.

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg